Enliven Therapeutics, Inc. (NASDAQ:ELVN) Stock Position Lessened by Acuta Capital Partners LLC

Acuta Capital Partners LLC trimmed its holdings in shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN - Free Report) by 9.8% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 267,368 shares of the company's stock after selling 29,000 shares during the quarter. Enliven Therapeutics makes up about 6.1% of Acuta Capital Partners LLC's investment portfolio, making the stock its 5th largest holding. Acuta Capital Partners LLC owned approximately 0.55% of Enliven Therapeutics worth $6,016,000 as of its most recent SEC filing.

Several other institutional investors have also added to or reduced their stakes in ELVN. Tower Research Capital LLC TRC raised its stake in shares of Enliven Therapeutics by 230.2% in the fourth quarter. Tower Research Capital LLC TRC now owns 1,598 shares of the company's stock worth $36,000 after buying an additional 1,114 shares during the period. KLP Kapitalforvaltning AS purchased a new position in shares of Enliven Therapeutics during the 4th quarter valued at $97,000. ExodusPoint Capital Management LP bought a new position in Enliven Therapeutics in the 4th quarter worth $200,000. China Universal Asset Management Co. Ltd. increased its stake in Enliven Therapeutics by 14.0% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 10,360 shares of the company's stock worth $233,000 after buying an additional 1,275 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD lifted its position in shares of Enliven Therapeutics by 17.0% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 13,627 shares of the company's stock valued at $307,000 after acquiring an additional 1,980 shares in the last quarter. 95.08% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In related news, CFO Benjamin Hohl sold 3,250 shares of the stock in a transaction on Thursday, February 27th. The stock was sold at an average price of $20.41, for a total transaction of $66,332.50. Following the sale, the chief financial officer now owns 13,000 shares in the company, valued at approximately $265,330. This represents a 20.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CEO Samuel Kintz sold 12,500 shares of the business's stock in a transaction on Monday, March 17th. The shares were sold at an average price of $20.83, for a total transaction of $260,375.00. Following the transaction, the chief executive officer now owns 990,392 shares in the company, valued at $20,629,865.36. This trade represents a 1.25 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 66,751 shares of company stock valued at $1,331,288 over the last ninety days. 29.20% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright lifted their target price on Enliven Therapeutics from $37.00 to $39.00 and gave the company a "buy" rating in a research note on Friday, March 21st.

Enliven Therapeutics Stock Up 3.3 %

Enliven Therapeutics stock traded up $0.66 during midday trading on Friday, reaching $20.51. 221,177 shares of the stock traded hands, compared to its average volume of 259,995. Enliven Therapeutics, Inc. has a 12 month low of $13.30 and a 12 month high of $30.03. The stock's fifty day moving average is $19.17 and its 200-day moving average is $22.38. The stock has a market cap of $1.01 billion, a P/E ratio of -10.79 and a beta of 1.07.

Enliven Therapeutics (NASDAQ:ELVN - Get Free Report) last announced its quarterly earnings results on Thursday, March 13th. The company reported ($0.46) earnings per share for the quarter, topping the consensus estimate of ($0.53) by $0.07. The business had revenue of $0.03 million during the quarter. On average, equities analysts predict that Enliven Therapeutics, Inc. will post -1.95 EPS for the current fiscal year.

Enliven Therapeutics Company Profile

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.